glp-1 updates Clinical Practice Updates: February 2026 Key Developments GLP-1 Clinical Practice Updates: May
Description
On the other hand, compounded semaglutide is made by pharmacies without FDA oversight, meaning it is not subject to the same regulatory standards
Survodutide: targeting the liver as well as the waistline Developed jointly by Boehringer Ingelheim and Zealand Pharma, survodutide is a once-weekly dual agonist of the GLP-1 and glucagon receptors
By now, unless you reside on Mars, youre plenty familiar with the names Ozempic and Wegovy
Patients should clarify which medications may be appropriate for their specific situation during the consultation process
these drugs include, but are not limited to, other carbonic anhydrase inhibitors and drugs with anticholinergic activity
GLP-1 receptor agonists and kidney protection
